Aripiprazole Lauroxil
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Dec 1, 2015 → Jul 11, 2017
NCT ID
NCT02634320About Aripiprazole Lauroxil
Aripiprazole Lauroxil is a approved stage product being developed by Alkermes for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02634320. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05662306 | Approved | Terminated |
| NCT02636842 | Phase 1 | Completed |
| NCT02634320 | Approved | Completed |
| NCT02320032 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia